AR and prostate carcinoma: This is, however, altered in prostate cancer, where the AR elicits an aberrant gene expression program due to gain or loss of binding sites [8,9,10] and to reactivation of developmental epigenetic processes [11], ultimately leading to uncontrolled tumor proliferation.